• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Gilead Gets Some Serious Play

I wouldn't be a buyer of Gilead on the coronavirus news, I'd be a buyer because the yield and chart look pretty darn good.
By TIMOTHY COLLINS
Feb 24, 2020 | 11:50 AM EST
Stocks quotes in this article: GILD

The most common question I'm getting from friends and email is what should I buy to benefit from the coronavirus?

At first glance, it sounds a bit cold, but traders and investors constantly search for opportunities. That doesn't mean you don't care, and some even hope they are wrong. Additionally, many are searching for a quick trade, not a long-term investment. Does anyone really want to make their fortune from the death and suffering of others? We won't answer that, but let's hope it is a resounding no.

With people clamoring for trade ideas surrounding the virus, it should be no surprise there are several virtually unknown small biotechs seeing speculative pops, but when a big name like Gilead Sciences (GILD) hits the headlines, it gets some serious play. It's important to note a company with a nearly $100 billion market cap won't see the same upside as some microcap biotech, but it also won't come with the potential of turning you into a bagholder.

Gilead closed just under $70 on Friday, but opened near $74 on news that a WHO team said the company's remdesivir drug is the only one with real efficacy against coronavirus. That's enough to get many traders excited, but it's one team and not the results of a trial. There are so many variables that go into that statement which makes it impossible to draw the conclusion the drug will be effective on a large scale. Once again, we're back to speculation.

Before the news, Gilead shares were trading in a wide weekly ascending triangle with a rising support level currently at $63 and resistance at $70. The gap higher this morning now creates a new support level of $70 with highs from the second half of 2018 becoming resistance at $74. If the stock can hold higher this week, then I suspect the bullish crossovers in the the Full Stochastics and Chaikan Oscillator indicators will hold providing bulls with some momentum and volume support.

Coronavirus aside, GILD looks fantastic above $70. I wouldn't use the virus as my primary reason for acquisition, but in a rough market, this appears to be one that could hold if the virus continues to spread or benefit from a strong technical pattern if the market rallies. I like the idea it can win on two fronts. While I'd like to see more growth on the fundamental side and a better forecast for 2020, it isn't what I would call expensive and offers a 4% dividend.

I wouldn't be a buyer of Gilead on the coronavirus news, I'd be a buyer because the yield and chart look pretty darn good. This stock appears to be a solid fit for a growth and income portfolio for moderate risk and above.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins had no position in the securities mentioned.

TAGS: Drug Approvals | Investing | Markets | Options | Stocks | Technical Analysis | Trading | Pharmaceuticals | Stock of the Day

More from Investing

Price Targets: How They Mislead and How They Can be Used

James "Rev Shark" DePorre
Jan 23, 2021 10:00 AM EST

The main problem with price targets is that they are a static number in a dynamic situation.

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login